This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lesnik, P. Articles by Chapman, M. J. Search for Related Content PubMed PubMed Citation Articles by Lesnik, P. Articles by Chapman, M. J.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:979-988.)
© 1997 American Heart Association, Inc.

Articles

Impact of a Combination of a Calcium Antagonist and a ß-Blocker on Cell- and Copper-Mediated Oxidation of LDL and on the Accumulation and Efflux of Cholesterol in Human Macrophages and Murine J774 Cells

Philippe Lesnik; Christiane Dachet; Laure Petit; Martine Moreau; Sabine Griglio; Philippe Brudi; ; M. John Chapman

From the Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherches sur Les Lipoprotéines et l'Athérogénèse, Hôpital de la Pitié, Paris; and Zeneca-Pharma, Cergy (P.B.), France.

Correspondence to Philippe Lesnik or M. John Chapman, Unité de Recherches sur Les Lipoprotéines et l'Athérogénèse, U-321, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83, Bd de l'Hôpital, 75651 Paris Cedex 13, France.

Abstract Calcium antagonists and ß-blockers may retard or inhibit atherogenesis. In the absence of data pertaining to the potential cardioprotective action of an association of such agents, we have investigated the impact of nifedipine and atenolol, alone or in combination, on the capacity of monocyte-macrophages (ex vivo) and copper ions (in vitro) to oxidize LDL and on intracellular metabolism and efflux of free and esterified forms of cholesterol in human macrophages and foam cells. At concentrations up to 100 µmol/L, atenolol had no effect on the oxidative resistance of LDL; on the contrary, nifedipine displayed a significant dose-dependent capacity to protect LDL during copper-mediated oxidation (100 µmol/L; P<.001). Using a DPPH radical generating system, nifedipine was shown to exert free radical–trapping activity (molar ratio of scavenging activity, nifedipine:-tocopherol, 1:114). The addition of atenolol to nifedipine was without effect on the antioxidant activity of the calcium antagonist. In experiments in which oxidative modification was mediated by monocyte-macrophages, nifedipine but not atenolol conserved its antioxidant capacity. Furthermore, we demonstrated that association of atenolol with nifedipine did not modify the antioxidant properties of nifedipine itself. Using a human monocyte-derived macrophage culture system, nifedipine, atenolol, or a combination of the two drugs was ineffective in inhibiting foam cell formation induced by acetylated LDL or oxidized LDL. However, atenolol (100 µmol/L) increased cellular accumulation of cholesteryl ester (+17%; P<.05), whereas nifedipine (100 µmol/L) decreased total cholesterol (-37.4%; P<.05) accumulation induced by acetylated LDL in the mouse macrophage cell line J774. A combination of the two drugs neutralized these antagonistic effects. None of these results were reproduced during the oxidized LDL–induced transformation of murine J774 cells into foam cells. Furthermore, cholesterol efflux from preloaded human macrophages was equally unaffected by the addition of the drugs alone or in combination. It therefore seems unlikely that the beneficial effect of atenolol on coronary heart disease is mediated by changes in either LDL oxidizability or cholesterol metabolism in human macrophages and foam cells. Our findings with nifedipine suggest, however, that this calcium antagonist may potentially exert antiatherosclerotic properties via a reduction of the oxidative modification of LDL, thereby affecting a reduction in foam cell formation and in the pathophysiological cellular activities of oxidized lipids, rather than by inducing a direct reduction in cholesterol accumulation in human foam cells of macrophage origin.

Key Words: atenolo1 • nifedipine • monocytes • LDL • macrophages • oxidation

This article has been cited by other articles:

				J. E. Nettleship, T. H. Jones, K. S. Channer, and R. D. Jones Physiological Testosterone Replacement Therapy Attenuates Fatty Streak Formation and Improves High-Density Lipoprotein Cholesterol in the Tfm Mouse: An Effect That Is Independent of the Classic Androgen Receptor Circulation, November 20, 2007; 116(21): 2427 - 2434. [Abstract] [Full Text] [PDF]

				M. C. Verhaar, M. L.H. Honing, T. van Dam, M. Zwart, H. A. Koomans, J. J.P. Kastelein, and T. J. Rabelink Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids Cardiovasc Res, June 1, 1999; 42(3): 752 - 760. [Abstract] [Full Text] [PDF]